Abstract 5106
Background
Obesity is a well-known risk factor for colorectal cancer (CRC), the relative risk being higher in men than in women, and for colon than for rectal cancer. Whether this risk differs by sidedness of colon cancer and sex, has however not yet been explored.
Methods
Among 28098 participants in the Malmö Diet and Cancer study, 11063 men and 17035 women, 584 incident CRC cases had been registered by Dec 31 2008. Seven anthropometric factors; height, weight, bodyfat%, hip circumference, waist circumference, BMI and waist-hip ratio (WHR) were categorized into quartiles (Q). Hazard ratios (HR) of CRC risk according to tumour location (right colon, left colon, rectum) and sex were calculated using multivariable Cox regression models, adjusted for age, smoking, educational level and alcohol intake.
Results
In men, several anthropometric factors were associated with an increased risk of right-sided colon cancer (HR for Q1[ref]-Q4 for weight 1.0, 1.67, 1.99, 2.88, ptrend= 0.001; waist circumference 1.0, 0.64, 1.59, 2.03, ptrend= 0.002; WHR 1.0, 0.73, 1.93, 1.89, ptrend= 0.004; BMI 1.0, 1.29, 1.50, 2.64, ptrend= 0.001), only WHR with left-sided colon cancer (1.0, 1.26, 1.94, 2.06, ptrend= 0.021), and none with rectal cancer. In women, body size was not associated with risk for neither right-sided nor left-sided colon cancer, only with rectal cancer (bodyfat% 1.0, 1.57, 2.18, 1.94, ptrend= 0.032, hip circumference 1.0, 1.76, 1.45, 2.18, ptrend= 0.033). Significant interactions with sex were denoted for hip circumference (p = 0.032) and BMI (p = 0.026) in relation to risk of right-sided colon cancer.
Conclusions
These data unveil a sexual dimorphism in the relationship between obesity and right-sided colon cancer, only being evident in men. As right-sided tumours are otherwise more common in women, hormonal factors may be particularly influential in their carcinogenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lund University.
Funding
The Swedish Cancer Society, the Swedish Research Council, the Swedish Government Grant for Clinical Research, the Mrs Berta Kamprad Foundation, Lund University Faculty of Medicine and University Hospital Research Grants.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3278 - Immune-Related Gene Expression Profiling after Neoadjuvant Chemotherapy (NACT) of Ovarian High-Grade Serous Carcinoma
Presenter: Luis Manso
Session: Poster Display session 2
Resources:
Abstract
4906 - Tumor-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A restrospective study
Presenter: Sara Giovannoni
Session: Poster Display session 2
Resources:
Abstract
3919 - Prognostic significance of elements of the adaptive immunity in the microenvironment of epithelial ovarian cancer.
Presenter: Periklis Foukas
Session: Poster Display session 2
Resources:
Abstract
5139 - Neutrophil-to-lymphocyte ratio predicts platinum sensitivity in epithelial ovarian cancer patients: a MITO24 retrospective study
Presenter: Alberto Farolfi
Session: Poster Display session 2
Resources:
Abstract
4212 - The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC)
Presenter: Marc Cucurull Salamero
Session: Poster Display session 2
Resources:
Abstract
5123 - TP53 Hotspot mutations as immunoreactive neoantigens define a signature with differential survival outcomes in advanced ovarian cancer
Presenter: Marica Garziera
Session: Poster Display session 2
Resources:
Abstract
3795 - Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients
Presenter: Dominique Berton-Rigaud
Session: Poster Display session 2
Resources:
Abstract
2359 - Phase II study: Letrozole maintenance therapy after first line chemotherapy in patients with advanced serous and endometrioid ovarian cancer
Presenter: Alexandra Tyulyandina
Session: Poster Display session 2
Resources:
Abstract
3619 - Baseline IPI (Immune Prognostic Index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI).
Presenter: Felix Blanc-Durand
Session: Poster Display session 2
Resources:
Abstract
3474 - Preselecting tumor-infiltrating lymphocyte subsets to implement adoptive inmmunotherapy in ovarian cancer
Presenter: Diego Salas-Benito
Session: Poster Display session 2
Resources:
Abstract